Prevents angina pectoris due to coronary artery disease. ANDA 214115, held by Shandong. Isosorbide Mononitrate.
As of Nov 16, 2026, ANDA 214115 (Isosorbide Mononitrate), held by Shandong, was first approved by FDA on Apr 29, 2022, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Isosorbide mononitrate extended-release tablets are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 29, 2022 | Original application | Approved | None posted |
| Isosorbide Mononitrate120MG · tablet, extended release;oral | Isosorbide Mononitrate | Rx |
| Isosorbide Mononitrate30MG · tablet, extended release;oral | Isosorbide Mononitrate | Rx |
| Isosorbide Mononitrate60MG · tablet, extended release;oral | Isosorbide Mononitrate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters